Champagne D., Dupuy J. B., Rochford J., Poirier J. (2002). Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task, Neuroscience, 114(3), 641-54.

Poirier J. (2002). Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action, Int J Clin Pract Suppl(127), 6-19.

Poirier J. (2002). Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's Disease: From risk factors to therapeutic targets . In Gauthier S. & Cummings J. L. (Eds.) , Alzheimer's Disease and Related Disorders Annual (pp. 1-23). Martin Dunitz Ltd.

Poirier J. (2002). High blood pressure and apolipoprotein E4: A true synergistic effect on late life cognitive function, Stroke, 32, 2888-2889.

Poirier J., Panisset M. (2002). Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's disease, Adv Behav Biol, 51, 39-43.

Prat A., Biernacki K., Lavoie J. F., Poirier J., Duquette P., Antel J. P. (2002). Migration of multiple sclerosis lymphocytes through brain endothelium, Arch Neurol, 59(3), 391-7.

Schappert K., Sevigny P., Poirier J. (2002). Apolipoprotein E: A pharmacogenomic marker used in the treatment of Alzheimer's disease . In B. Lerer (Ed.) , Pharmacogenetics of psychotropic drugs (pp. 358-369). Cambridge University Press.

Zetterberg H., Palmer M., Ricksten A., Poirier J., Palmqvist L., Rymo L., Zafiropoulos A., Arvanitis D. A., Spandidos D. A., Blennow K. (2002). Influence of the apolipoprotein E epsilon4 allele on human embryonic development, Neurosci Lett, 324(3), 189-92.

de Leon M. J., Segal S., Tarshish C. Y., DeSanti S., Zinkowski R., Mehta P. D, Convit A., Caraos C., Rusinek H., Tsui W., Saint Louis L. A., DeBernardis J., Kerkman D., Qadri F., Gary A., Lesbre P., Wisniewski T., Poirier J., Davies P. (2002). Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment, Neurosci Lett , 333 (3 ), 183-186.